



August 11, 2016

## **Biocept Expands Distribution of Liquid Biopsy Tests to the Philippines**

### **Enters into agreement with HarlePhil Ventures, marking the Company's third announced international distribution partnership**

SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces a preferred provider agreement with HarlePhil Ventures, Inc., a wholly owned subsidiary of The Harle Group Inc., to market and distribute Biocept's Target Selector™ liquid biopsy assays in the Republic of the Philippines. All diagnostic testing services under this agreement will be performed in Biocept's San Diego-based CLIA-certified laboratory with HarlePhil Ventures, Inc. having responsibility for sales, marketing, distribution, and reimbursement of the Company's liquid biopsy platform. Additional terms of the transaction were not disclosed.



"This is our first distribution agreement in Southeast Asia and marks a key milestone in our goal of expanding the distribution of our proprietary testing services into international markets," said Michael Nall, President and CEO of Biocept. "We are delighted to partner with HarlePhil Ventures to offer cancer patients in the Philippines access to our liquid biopsy platforms. We have now announced three international distribution agreements, with our liquid biopsy tests also available in Israel and Mexico, and we anticipate expanding into additional international markets in the future."

"Our new Biocept offering aligns with our corporate commitment to bring cutting-edge commercial diagnostics services to our physician customers," said Roy J. Militante, Chief Executive Officer of The Harle Group. "Molecular tumor profiling and monitoring using a simple blood draw can provide physicians with important information when making personalized treatment decisions for their patients with cancer, without invasive surgical biopsies."

#### **About The Harle Group**

The Harle Group is a leading distributor of life science technologies in the Philippines. The company believes that the future of medicine lies in the understanding of the three billion units of DNA that make up a human genome. Life science companies have begun to show success in the fields of cancer, cardiac health, pain management, pre-natal condition, organ transplants and many more. The Harle Group intends to extend each success story to target markets in Asia. Additional information is available at [www.harlegroup.com](http://www.harlegroup.com).

#### **About Biocept**

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit [www.biocept.com](http://www.biocept.com).

#### **Forward-Looking Statements Disclaimer Statement**

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements

and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, our ability to expand the distribution of our proprietary testing services into international markets, and our ability to continue the growth and commercialization of our liquid biopsy testing services, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at [www.sec.gov](http://www.sec.gov).

Logo - <http://photos.prnewswire.com/prnh/20151013/276540LOGO>

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/biocept-expands-distribution-of-liquid-biopsy-tests-to-the-philippines-300312254.html>

SOURCE Biocept, Inc.

News Provided by Acquire Media